Aclaris Therapeutics, Inc.
ACRS
$1.15
$0.076.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,172.77% | 30.95% | 35.15% | -1,036.22% | 94.90% |
| Total Depreciation and Amortization | -20.11% | -26.03% | -0.41% | 6.58% | 4.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,225.58% | 22.59% | -36.53% | 126.04% | -345.45% |
| Change in Net Operating Assets | -103.88% | 646.96% | 48.02% | -167.85% | 519.66% |
| Cash from Operations | -140.63% | 278.54% | 40.80% | -207.87% | 72.47% |
| Capital Expenditure | -- | -100.00% | 110.37% | 69.39% | -425.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,274.35% | 506.25% | -104.05% | 112.34% | -75.50% |
| Cash from Investing | -3,274.35% | 514.69% | -104.00% | 122.95% | -76.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 249,900.00% | -- | -- | -- | 5,733.33% |
| Repurchase of Common Stock | -3,230.00% | 9.09% | 80.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 338,900.00% | 300.00% | 80.00% | -212.24% | 156.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.00% | 290.80% | -222.19% | -581.74% | -89.38% |
